Phase Ib trial shows ALECSAT adoptive cell therapy plus carboplatin–gemcitabine is safe and yields promising responses in metastatic TNBC, with higher infused CD8+ T-cell doses correlating with longer disease control.
Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Caused by Pola-R-CHOP: A Case Report - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41267725/
Chemotherapy regimens, especially for haematologic malignancies, have been increasingly implicated in drug reactions with eosinophilia and systemic symptoms (DRESS) syndrome. We present a case of DRESS syndrome in a patient...
DLBCL patient on pola-R-CHOP developed severe rash and systemic illness diagnosed as DRESS; steroids led to improvement despite CMV reactivation complicating management. Highlights need for early recognition in oncology patients.
Study Protocol of SURVIVE HERoes (NCT06643585): Trastuzumab Deruxtecan for molecular relapse in HER2+/ Low early breast cancer with ctDNA positivity after primary therapy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41259337/
Treating ctDNA positive patients without radiographic signs of recurrence is a novel approach. If SURVIVE HERoes and similar studies targeting MRD will be positive, this may lead the way to...
SURVIVE HERoes is a phase III trial testing trastuzumab deruxtecan versus standard care in HER2+/low early breast cancer with ctDNA-positive molecular relapse, aiming to improve ctDNA clearance and advance MRD-guided therapy.
Diagnosis of Ectopic Intrathyroidal Parathyroid Adenoma with Nodular Goiter by 18F Fluorocholine: A Case Report - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35603434/
The occurrence of ectopic intrathyroidal parathyroid adenoma (EPTA) is very rare, which causes some difficulties in diagnosis and complicates treatment. In addition, the occurrence of EPTA with nodular goiter (NG)...
Ectopic intrathyroidal parathyroid adenoma with nodular goiter is rare and challenging to diagnose; this case highlights the value of fluorocholine imaging and cytology for accurate identification and management.
Cancer survivorship programs for patients from culturally and linguistically diverse (CALD) backgrounds: a scoping review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37572196/
Ensuring culturally sensitive and specific delivery of cancer survivorship programs and interventions is paramount in providing optimal care for survivors from CALD backgrounds.
This review of 26 studies on cancer survivorship programs for culturally and linguistically diverse populations found most U.S.-based, focusing on breast cancer; multimodal, bilingual, community-informed interventions improved quality of life, highlighting cultural sensitivity’s importance despite barriers.